Guidelines on the management of valvular heart disease [4]

European Heart Journal

Volumn 28, Issue 10, 2007, Pages 1267-

  Aguiar Souto, Pablo ^a   Mirelis, Jesús G ^a   Silva Melchor, Lorenzo ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

AORTA VALVE REGURGITATION; FETUS DISEASE; HEART VALVE REGURGITATION; HUMAN; LETTER; MITRAL VALVE REGURGITATION; PRACTICE GUIDELINE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK ASSESSMENT; VALVULAR HEART DISEASE; FEMALE; NOTE; PREGNANCY COMPLICATION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIURETICS; FEMALE; FETAL DISEASES; GUIDELINES AS TOPIC; HEART VALVE DISEASES; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 34548329586     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm094     Document Type: Letter

References (5)

1. Vahanian A. Guidelines on the management of valvular heart disease. Eur Heart J 2007;28:230-268.
2. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotension receptor antagonists. Early Hum Dev 2006;82:23-28.
3. Buttar HS. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development. Mol Cell Biochem 1997;176:61-71.
4. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology 1994;50:399-409.
5. Cooper WO. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006;354:2443-2451.